Literature DB >> 1679995

Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies.

M Favrot1, V Combaret, E Goillot, J P Wagner, E Bouffet, F Mazingue, A Thyss, P Bordigoni, G Delsol, C Bailly.   

Abstract

Immunohistological detection of P-glycoprotein (P-gp) with monoclonal antibody C219 was performed on serial sections of 37 neuroblastoma specimens representative of the different forms of the disease, from stage 1 ganglioneuroma to stage 4 neuroblastoma. Malignant cells, irrespective of their degree of maturation varying from neuroblasts to ganglion cells, were negative on all specimens. The expression of P-glycoprotein was detected in nine specimens, but it was restricted to normal cells within the tumour. In four specimens, C219 reacted with normal infiltrating cells in the stroma (i.e. monocytes, histiocytes or fibroblasts) representing 5 to 10% of the total population within the section; in three specimens, the residual adrenal gland was strongly positive, and in two ganglioneuromas, a weak reactivity of C219 was observed on a few satellite cells and schwann cells. Three of 15 biopsies obtained at diagnosis contained normal P-gp positive cells: two were classified as stage 1 ganglioneuromas; one was a typical stage 4 composite tumours with positive histiocytes and fibroblasts in the well-differentiated counterpart. Six of 22 biopsies obtained after patients had received our current protocol of chemotherapy contained normal P-gp positive cells: five were partially differentiated and necrotic under the effect of chemotherapy; only one positive specimen was classified as undifferentiated neuroblastoma. Among negative specimens from previously treated patients, one was obtained from a patient in relapse after high-dose chemotherapy and ABMT, two were obtained from patients who had not responded to induction therapy, and six from patients in partial remission after induction therapy. The clinical evolution was very similar in both groups of patients with P-gp negative or positive biopsies. These findings suggest that the quantitative assessment of MDR RNA by northern blotting on fresh homogenates is likely to overestimate its expression on neuroblastoma cells, and that the mechanism of chemoresistance in widespread neuroblastoma is less likely to be associated with P-gp expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679995      PMCID: PMC1977522          DOI: 10.1038/bjc.1991.282

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Reversal of multidrug resistance.

Authors:  B A Chabner; W Wilson
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

2.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

Authors:  T P Miller; T M Grogan; W S Dalton; C M Spier; R J Scheper; S E Salmon
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

4.  Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.

Authors:  A Nakagawara; K Kadomatsu; S Sato; K Kohno; H Takano; K Akazawa; Y Nose; M Kuwano
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

5.  Expression of the multidrug resistance, MDR1, gene in neuroblastomas.

Authors:  L J Goldstein; A T Fojo; K Ueda; W Crist; A Green; G Brodeur; I Pastan; M M Gottesman
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

6.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

7.  MDR1 gene expression in lung cancer.

Authors:  S L Lai; L J Goldstein; M M Gottesman; I Pastan; C M Tsai; B E Johnson; J L Mulshine; D C Ihde; K Kayser; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

8.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

Authors:  C Cordon-Cardo; J P O'Brien; J Boccia; D Casals; J R Bertino; M R Melamed
Journal:  J Histochem Cytochem       Date:  1990-09       Impact factor: 2.479

Review 9.  P-glycoproteins in pathology: the multidrug resistance gene family in humans.

Authors:  R S Weinstein; J R Kuszak; L F Kluskens; J S Coon
Journal:  Hum Pathol       Date:  1990-01       Impact factor: 3.466

10.  Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation.

Authors:  S E Bates; L A Mickley; Y N Chen; N Richert; J Rudick; J L Biedler; A T Fojo
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 5.069

View more
  7 in total

1.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 2.  Neuroblastoma.

Authors:  S Shah; Y Ravindranath
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 1.967

Review 3.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 5.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 6.  Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.

Authors:  Anna Alisi; William C Cho; Franco Locatelli; Doriana Fruci
Journal:  Int J Mol Sci       Date:  2013-12-18       Impact factor: 5.923

7.  Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia.

Authors:  A Gruber; S Vitols; S Norgren; I Areström; C Peterson; M Björkholm; P Reizenstein; H Luthman
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.